Together with evidence of decreases in butyrate-producing and other interactive bacteria, it is reasonable to suggest that colonic PPARG could be a druggable target for the treatment of HTN, particularly considering its highly significant interactions with Mbx-2044 and Treprostinil.
← all excerpts
Influence of Butyrate on Impaired Gene Expression in Colon from Patients with High Blood Pressure.
1
—
—